NBIX
Neurocrine Biosciences Inc
138.40$
-0.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | +45.0% | +55.4% | +12.3% | +32.3% | +14.9% | +52.7% | +31.5% | |
| – | +22.0% | +44.0% | +65.2% | +66.7% | +85.0% | +16.2% | +26.7% | +43.1% | +36.5% | +27.2% | +11.1% | |
| – | +173.5% | +0.3% | +49.4% | +36.6% | +29.6% | +32.8% | +34.2% | +29.0% | +12.2% | +0.6% | +11.5% | |
| – | +250.0% | -0.1% | +61.5% | +41.8% | +32.6% | -348.1% | – | +86.4% | – | – | – | |
| – | +440.9% | -33.6% | -252.3% | – | – | – | – | -503.6% | – | -168.1% | – | |
| – | +20.0% | +112.4% | +68.9% | +257.3% | -40.7% | -25.9% | +114.7% | -29.5% | +71.5% | +35.0% | -11.0% | |
| – | +85.8% | – | -322.4% | -3.3% | -13.1% | – | -3,275.6% | +36.0% | +163.7% | -72.9% | +108.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +99.7% | -99.1% | +480.1% | +113.0% | -7.5% | +6.5% | -5.5% | +62.5% | -100.0% | – | -44.1% | |
| – | +0.0% | +0.0% | +0.0% | -137.2% | +0.0% | +0.0% | -99.9% | +278,900.0% | -100.0% | – | -100.0% | |
| – | +99.7% | -99.1% | +21,517.0% | -94.3% | +9.8% | -587.0% | – | -955.1% | – | -845.3% | -92.1% | |
| – | – | -78.8% | +1,766.7% | -165.5% | – | – | +105.5% | -147.7% | – | – | – | |
| – | – | – | – | – | +72.7% | +64.5% | +7.1% | +38.5% | +12.0% | +54.1% | +34.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.